165 related articles for article (PubMed ID: 22021166)
1. A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice.
Berman-Booty LD; Sargeant AM; Rosol TJ; Rengel RC; Clinton SK; Chen CS; Kulp SK
Toxicol Pathol; 2012; 40(1):5-17. PubMed ID: 22021166
[TBL] [Abstract][Full Text] [Related]
2. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.
Jain AK; Raina K; Agarwal R
Cell Cycle; 2013 May; 12(10):1598-604. PubMed ID: 23624841
[TBL] [Abstract][Full Text] [Related]
3. Capsaicin reduces the metastatic burden in the transgenic adenocarcinoma of the mouse prostate model.
Venier NA; Yamamoto T; Sugar LM; Adomat H; Fleshner NE; Klotz LH; Venkateswaran V
Prostate; 2015 Sep; 75(12):1300-11. PubMed ID: 26047020
[TBL] [Abstract][Full Text] [Related]
4. Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice.
Berman-Booty LD; Thomas-Ahner JM; Bolon B; Oglesbee MJ; Clinton SK; Kulp SK; Chen CS; La Perle KM
Toxicol Pathol; 2015 Feb; 43(2):186-97. PubMed ID: 24742627
[TBL] [Abstract][Full Text] [Related]
5. A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model.
Suttie A; Nyska A; Haseman JK; Moser GJ; Hackett TR; Goldsworthy TL
Toxicol Pathol; 2003; 31(1):31-8. PubMed ID: 12597447
[TBL] [Abstract][Full Text] [Related]
6. Lobe-specific lineages of carcinogenesis in the transgenic adenocarcinoma of mouse prostate and their responses to chemopreventive selenium.
Wang L; Zhang J; Zhang Y; Nkhata K; Quealy E; Liao JD; Cleary MP; Lü J
Prostate; 2011 Sep; 71(13):1429-40. PubMed ID: 21360561
[TBL] [Abstract][Full Text] [Related]
7. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
9. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
Tepaamorndech S; Huang L; Kirschke CP
Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
[TBL] [Abstract][Full Text] [Related]
10. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease.
Adhami VM; Siddiqui IA; Sarfaraz S; Khwaja SI; Hafeez BB; Ahmad N; Mukhtar H
Clin Cancer Res; 2009 Mar; 15(6):1947-53. PubMed ID: 19276266
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia.
Lotan TL; Lyon M; Huo D; Taxy JB; Brendler C; Foster BA; Stadler W; Rinker-Schaeffer CW
J Pathol; 2007 Aug; 212(4):386-94. PubMed ID: 17577251
[TBL] [Abstract][Full Text] [Related]
12. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
13. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP).
Mentor-Marcel R; Lamartiniere CA; Eltoum IE; Greenberg NM; Elgavish A
Cancer Res; 2001 Sep; 61(18):6777-82. PubMed ID: 11559550
[TBL] [Abstract][Full Text] [Related]
14. Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model: A good alternative to study PCa progression and chemoprevention approaches.
Kido LA; de Almeida Lamas C; Maróstica MR; Cagnon VHA
Life Sci; 2019 Jan; 217():141-147. PubMed ID: 30528182
[TBL] [Abstract][Full Text] [Related]
15. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
[TBL] [Abstract][Full Text] [Related]
16. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.
Chiaverotti T; Couto SS; Donjacour A; Mao JH; Nagase H; Cardiff RD; Cunha GR; Balmain A
Am J Pathol; 2008 Jan; 172(1):236-46. PubMed ID: 18156212
[TBL] [Abstract][Full Text] [Related]
17. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Gupta S; Adhami VM; Subbarayan M; MacLennan GT; Lewin JS; Hafeli UO; Fu P; Mukhtar H
Cancer Res; 2004 May; 64(9):3334-43. PubMed ID: 15126378
[TBL] [Abstract][Full Text] [Related]
18. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
Peek EM; Song W; Zhang H; Huang J; Chin AI
Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
[TBL] [Abstract][Full Text] [Related]
19. Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model.
Morey Kinney SR; Smiraglia DJ; James SR; Moser MT; Foster BA; Karpf AR
Mol Cancer Res; 2008 Aug; 6(8):1365-74. PubMed ID: 18667590
[TBL] [Abstract][Full Text] [Related]
20. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
